Enamine Extend Collaboration With Prominent Swiss Biotech
February 24 2021 - 4:00AM
Business Wire
A new multi-year drug discovery agreement will focus on CNS
drug discovery
Enamine Ltd. a provider of
drug discovery services empowered with the world’s largest
collections of building blocks, fragments and screening compounds
announced today that it has extended its long-standing research
collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:
ADXN), a clinical-stage pharmaceutical company specialized in
allosteric modulation-based drug discovery and development. Enamine
is providing Addex with its integrated capability in medicinal
chemistry, pharmacology and ADME/PK (Absorption, Distribution,
Metabolism, Excretion/Pharmacokinetics) to efficiently support
Addex’s small molecule CNS drug discovery programs.
The collaboration is
established under a Full Time Equivalent (FTE) model, serving
optimally the various research programs, with Addex Therapeutics
owning all resulting Intellectual Property Rights.
“Over many years of collaboration, we have witnessed the
enabling technology developments of Enamine in areas such as
parallel chemistry, analytics, ADME and biophysical screening
methods,” commented Jean-Philippe Rocher, Co-Head of Discovery and
Member of the Executive Management of Addex Therapeutics. “We have
been particularly impressed with Enamine’s sharp focus on the needs
of our programs and their commitment to customer service. The
immediate access we have to a broad chemical space coupled with
Enamine’s large synthetic toolbox has a direct positive impact to
advance our lead finding activities.”
Michael Bossert, Head Strategic Alliances at Enamine added: “In
the world of turmoil of last year, Enamine was adequately adapting
to the challenges, allowing another year of record revenue
achievement. Our continued innovation in chemistry and our unique
stock of over 225,000 building blocks available to our chemists
benefit to our customers and their discovery of the next stream of
medicines.” He continued: “We are delighted to extend our
collaboration with Addex Therapeutics; we are moving forward into
2021 with a great excitement.”
About Enamine Ltd. www.enamine.net
Established in Kyiv in 1991, Enamine is a global leading
designer and largest producer of building blocks (225,000+),
fragments (172,000+) and screening libraries (2.5M+ compounds).
Enamine provides expertise in advanced organic synthesis, library
synthesis, medicinal chemistry. In 2011 Enamine established a
pre-clinical service unit including ADME, in-vivo PK studies and
High Throughput Screening under the brand name “Bienta”, allowing
the company to tackle since that time fully integrated or
à-la-carte research programs.
About Addex Therapeutics
https://www.addextherapeutics.com
Addex Therapeutics is a clinical-stage pharmaceutical company
focused on the development and commercialization of an emerging
class of novel orally available small molecule drugs known as
allosteric modulators for neurological disorders. Allosteric
modulators offer several potential advantages over conventional
non-allosteric molecules and may offer an improved therapeutic
approach to conventional "orthosteric" small molecule or biological
drugs. Addex's allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex is listed on the NASDAQ Capital
Market and is trading under the ticker symbol "ADXN".
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005033/en/
Enamine Ltd. Michael Bossert m.bossert@enamine.net
Media Andrii Buvailo a.buvailo@enamine.net
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024